Adult-onset idiopathic opsoclonus-myoclonus syndrome
2022

Adult-onset Idiopathic Opsoclonus-Myoclonus Syndrome

publication Evidence: low

Author Information

Author(s): Zhang Xiaohan, Yan Wenjing, Song Yuqiang, Zhu Haifang, Sun Yanping

Primary Institution: The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China

Hypothesis

The study aims to raise awareness of opsoclonus-myoclonus-ataxia syndrome and improve diagnosis and treatment using immunotherapy.

Conclusion

Early diagnosis and treatment of opsoclonus-myoclonus-ataxia syndrome can lead to a better prognosis, and combined immunotherapy may reduce the incidence of refractory cases.

Supporting Evidence

  • Immunotherapies successfully treated the patient's opsoclonus, myoclonus, and ataxia.
  • The prevalence of residual sequela in adults with opsoclonus-myoclonus-ataxia syndrome is low.
  • Combined immunotherapy is expected to reduce the incidence of refractory and recurring opsoclonus-myoclonus-ataxia syndrome.

Takeaway

This study is about a rare condition that causes unusual eye movements and muscle spasms in adults, and it shows that treating it early can help people feel better.

Methodology

The study presents a case report and literature review on the syndrome's pathophysiology, clinical presentation, diagnosis, and treatment.

Limitations

The study is based on a single case report, which may limit the generalizability of the findings.

Participant Demographics

The case study involves a 33-year-old woman.

Digital Object Identifier (DOI)

10.5935/0004-2749.2022-0024

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication